Mitigating the aggregation challenge in immunocytokine production: Strategies during cell line development and purification optimization
Authors:
- Yanling WangYWYanling Wang
- Haoran QiuHQHaoran Qiu
- Wenqiang LiuWLWenqiang Liu
- Xichan HuXHXichan Hu
- Wilburt TamWTWilburt Tam
- Weibin ZhengWZWeibin Zheng
- Dana LeeDLDana Lee
- Qiang LiuQLQiang Liu
- Chun ChuCCChun Chu
- 3 January 2024
- journal article
- research article
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 203
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cytokines in the Treatment of MelanomaCurrent Oncology Reports, 2021
- Accelerating and de‐risking CMC development with transposon‐derived manufacturing cell linesBiotechnology and Bioengineering, 2021
- A cell line development strategy to improve a bispecific antibody expression purity in CHO cellsBiochemical Engineering Journal, 2021
- High-Throughput Generation of Bipod (Fab × scFv) Bispecific Antibodies Exploits Differential Chain Expression and Affinity CaptureScientific Reports, 2020
- Leap-In Transposases and Transposons Accelerate Cell Line DevelopmentGenetic Engineering & Biotechnology News, 2019
- Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapyAdvanced Drug Delivery Reviews, 2019
- Influence of molecular size on tissue distribution of antibody fragmentsmAbs, 2015
- The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification processJournal of Chromatography A, 2010
- Comparison of standard and new generation hydrophobic interaction chromatography resins in the monoclonal antibody purification processJournal of Chromatography A, 2008
- Downstream processing of monoclonal antibodies—Application of platform approachesJournal of Chromatography B, 2007